Histamed

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Histamed

Histamed is a specialized multi-component combination product, officially classified as a Dermatological Agent, intended for topical administration. Its structure combines multiple active chemical entities from distinct pharmacological classes, representing a strategy to manage complex skin reactions simultaneously.


What Type of Medicine is Histamed?

Histamed is defined by its complex, multi-modal profile, integrating components that are both synthetic and naturally derived. The formulation functions as a combination of H1 Antihistamines, a Glucocorticoid Corticosteroid, a Local Anesthetic, and Skin Protectants/Counterirritants. This combination is utilized for targeting skin irritations involving multiple symptoms, such as allergic reactions resulting in itching and inflammation. The inclusion of agents like Betamethasone provides an anti-inflammatory component that extends its therapeutic scope to address both the underlying immune response and surface symptoms.


What Active Ingredients Does Histamed Combine?

The product contains a strategic blend of active ingredients for layered symptom control. This composition includes multiple H1 antagonists (such as Cetirizine, Diphenhydramine Hydrochloride, and Chlorphenamine Maleate) which work to block the effects of histamine. The topical anesthetic Benzocaine is included for direct relief of discomfort; local anesthetics are utilized in topical preparations for immediate action against localized pain and itching. Additionally, the presence of Camphor, a counterirritant, further enhances the immediate sensory relief. This blend focuses on achieving both immediate symptom mitigation and inflammatory control within a single topical application, delivered in a Lipid Base or Aqueous Vehicle.


What is the General Purpose of Histamed’s Combination Approach?

The primary therapeutic purpose of Histamed’s multi-agent approach is to provide comprehensive symptomatic relief by simultaneously addressing the core components of localized skin irritation: the allergic response, the resulting inflammation, and the immediate discomfort of itching and pain. This coordinated action is intended to offer a broad initial response to complex hypersensitivity reactions by addressing multiple pathways of irritation within a single application.

Regulatory References

  1. NIH Topical Anesthetics Information

What side effects are possible with Histamed?

Possible side effects and safety information

The official safety documentation for Histamed, a multi-component topical agent, outlines its risk profile by classifying adverse reactions based on frequency and affected body systems, strictly according to regulatory standards.

Adverse Reaction Scope

The most frequently reported effects, officially classified as Common, are localized reactions at the application site, including a burning sensation, pruritus (itching), erythema (redness), and irritation. Less frequent reactions, categorized as Uncommon, involve changes to the skin such as striae, folliculitis, or skin atrophy (thinning), which are generally associated with prolonged use.

Adverse reactions are grouped by System-Organ Class in regulatory data, primarily listing effects under Skin and Subcutaneous Tissue Disorders. However, the safety profile formally documents the potential for rare, yet serious, risks in other systems. These include Endocrine Disorders, such as HPA axis suppression, linked to systemic absorption of the corticosteroid component, and Blood and Lymphatic System Disorders, listing the risk of Methemoglobinemia associated with the topical anesthetic component.

Regulatory Safety Considerations

The safety documentation defines specific limitations on use. Systemic adverse reactions, including HPA suppression and skin atrophy, are classified as being associated with prolonged or extensive use of the product. Furthermore, the pediatric population is explicitly noted as having an increased susceptibility to systemic adverse effects, such as HPA axis suppression, due to body-mass ratios. The official labeling restricts use on large surface areas or under occlusive dressings to mitigate these documented systemic risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Histamed overdose focuses on the potential for systemic toxicity, typically following accidental ingestion or massive topical application. Documented overdose presentations primarily involve Systemic H1 Antagonist Toxicity, which may manifest as profound drowsiness, sedation, dizziness, blurred vision, and dry mouth. In contrast, Central Nervous System (CNS) excitation, anxiety, and restlessness are specifically noted in pediatric patients.

The official profile lists severe and life-threatening outcomes, including seizures, coma, severe cardiac arrhythmias, and hypotension. A unique, serious hematologic risk is Methemoglobinemia, linked to the Benzocaine component, which presents as cyanosis (pale, gray, or blue-colored skin) and severe breathing difficulty.

Regulatory guidance states that individuals must seek immediate medical attention for any suspected overdose. Urgent medical help must be sought immediately if symptoms include collapse, seizures, unconsciousness, or cyanosis. Treatment is designated as symptomatic and supportive. While no specific antidote is known for the antihistamine components, Methylene Blue is indicated for the treatment of Methemoglobinemia. Hospital monitoring and supportive measures, such as activated charcoal, may be required for serious cases. Infants and young children are noted to be at greater risk for systemic effects, including HPA axis suppression from massive topical overuse.

Therapeutic Uses of Histamed

Histamed is primarily used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It contributes to improved day-to-day comfort during symptomatic periods. The therapeutic role of components like topical corticosteroids is aligned with addressing symptoms of redness, swelling, itching, and discomfort in various skin conditions.

It is commonly used across conditions presenting with acute episodes characterized by allergic or irritative states. It is relevant in situations involving symptomatic discomfort common to insect bites, minor allergic rashes, localized hives, acute eczema flares, and contact dermatitis. Applied in scenarios where additional management of discomfort is required, this approach helps address symptom clusters that may become intense or disruptive.

“The primary goal is to provide supportive relief when symptoms cluster into patterns requiring multi-component management, helping patients cope more steadily with difficult episodes.”

Histamed is relevant for managing the symptoms related to physical discomfort, including the immediate burning, stinging, and minor pain associated with skin irritation. This supportive action helps ease the overall symptom load when symptoms interfere with routine activities.


Quick Fact: Relevant for symptoms related to localized pruritus, inflammation, and sensory pain


Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Histamed is a combination product whose use is strictly defined by regulatory eligibility rules based on its active ingredients.

Populations Contraindicated

Use is Contraindicated for patients with a known hypersensitivity to any component (Benzocaine, Betamethasone, etc.). It must not be used on areas affected by untreated primary cutaneous infections (viral, fungal, or bacterial), Rosacea, Perioral Dermatitis, or Acne Vulgaris in the treatment area.

Age and Physiological Status

Use is Contraindicated in children under 2 years of age as per labeling. For children aged 2–12 years, use is severely Restricted to short durations and small surface areas to minimize systemic absorption risk. Use is Not Recommended during both Pregnancy and Lactation due to the potential for systemic exposure.

Eligibility Restrictions

Application is Prohibited on large body surface areas, broken skin, mucous membranes, or under occlusive dressings. Conditional use is advised by regulators for patients with severe Hepatic or Renal Impairment. The regulatory structure defines these groups as either Contraindicated, requiring Restricted Use, or Not Recommended to ensure population safety.

What should I know about interactions with other medicines?

Histamed, a first-generation antihistamine, has several documented interactions primarily concerning its effects on the central nervous system (CNS) and its anticholinergic properties.

Major Interactions (Avoid Use)

  • Monoamine Oxidase Inhibitors (MAOIs): Concurrent use with MAOIs, or within 14 days of stopping MAOI therapy, is contraindicated. This combination may intensify the effects of the antihistamine and potentially cause severe reactions, including hypertensive crisis (if a sympathomimetic is also present) or profound CNS effects.

Use with Caution (Risk of Additive Effects)

  • CNS Depressants: Caution is required with alcohol, sedatives, hypnotics, tranquilizers, opioid analgesics, and other antihistamines. The combination results in an additive CNS depressant effect, increasing the risk of drowsiness, sedation, respiratory depression, and impaired coordination.
  • Anticholinergic Drugs: Concurrent use with other anticholinergic agents (like some antidepressants or anti-Parkinsonian drugs) may potentiate adverse effects such as dry mouth, blurred vision, difficulty urinating, and severe constipation.
  • Specific Agents: Use with caution when combined with agents such as anticoagulants (e.g., oral anticoagulants), anti-arrhythmic agents, and certain drugs metabolized by the liver, including phenytoin and other anticonvulsants.
  • Antacids: If taking antacids containing aluminum, calcium, or magnesium, they should not be consumed within a two-hour period of taking this drug to avoid potential interference with absorption.

Mechanism of Action

Dual-Pathway Modulation of Inflammatory Signaling ️

This mechanism engages two distinct regulatory systems: H1 antagonists reduce inflammation by blocking histamine receptors and stabilizing vascular activity, while Betamethasone activates the Glucocorticoid Receptor ( GR) to modulate gene transcription. This dual approach affects both the immediate binding of inflammatory mediators and the sustained cellular production of pro-inflammatory proteins, contributing to the modulation of the inflammatory cascade and decreased fluid extravasation into tissues.


Modulation of Sensory Nerve Conduction via Voltage-Gated Channel Blockade

Benzocaine provides a direct effect by physically blocking Voltage-Gated Sodium Channels ( Nav Channels) within peripheral nerve fibers. This channel blockade prevents the Na^+ ion flux necessary to propagate an action potential. The resulting prevention of electrical impulse propagation interrupts the transmission of afferent signals from the skin to the central nervous system, resulting in localized alteration of sensory nerve input.


Superficial Sensory Modulation and Surface Tissue Effect

This domain involves Camphor's action on TRP sensory channels (e.g., TRPM8 and TRPV1) to induce a temporary alteration in somatosensory perception, followed by nerve desensitization. Additionally, Calamine acts as an astringent, precipitating superficial proteins to form a protective barrier. These complementary actions modulate immediate sensory input and alters the local tissue microenvironment.

Dosage and Administration Information

How to Use Histamed

This section outlines the high-level principles for the administration of Histamed, based on established protocols for multi-component topical agents.


Administration Scope

Feature Standard Guideline
Route of administration Topical (Dermal) application only. The preparation is to be applied directly to the surface of the skin.
Dosing schedule Apply a thin layer to cover the affected area. Total application must not exceed the prescribed maximum frequency, typically limited to four times per day.
Preparation requirements The application site should be clean and dry before administration. Avoid application to mucous membranes, eyes, or open wounds.
Age-group administration rules Use is not recommended for pediatric patients under 2 years of age. Reduced frequency or duration may be indicated for older adults based on labeling.

Use Protocol and Course Duration

Histamed is designated for symptom-driven use during acute episodes of localized irritation. The frequency pattern is generally set as two to four times daily based on symptomatic need, while adhering to the maximum limit.

The course duration is defined as short-term use, often limited to a maximum of 7 consecutive days. Application should be discontinued immediately upon symptom resolution to comply with standard protocols for topical corticosteroid combination products.

Special Procedural Conditions

Standard instructions require the avoidance of occlusive dressings (tight bandaging) over the application area unless explicitly directed by a healthcare professional. This use-context constraint is a core component of the administration protocol for Histamed, which is available in dosage forms including Cream, Ointment, Solution, or Lotion.

Recent Clinical Evidence

Histamed: Recent Clinical Evidence

Clinical research on this compound focuses primarily on evaluating its potential role in managing certain chronic pain conditions and specific types of headaches. The evidence base is built upon a series of Phase 3 and early-phase studies that characterize the compound's profile across different patient groups.


Phase 3 Trial Data (Chronic Pain)

Research has explored the potential for this compound to be associated with changes in chronic, moderate-to-severe pain levels. Clinical trials examined this compound in relation to pain management, typically comparing the compound's profile to a placebo group over a 12-week period. Secondary endpoints in these studies included evaluating patient-reported pain scores and assessing adverse events.


Specific Applications Investigated

Neuropathic Pain

Early-phase trials evaluated the compound in participants with two common forms of refractory neuropathic pain. The primary goal of these small, early-stage studies was to evaluate safety and tolerability profiles in this specific patient population. Studies also evaluated this compound in participants who had previously received traditional first-line treatments, aiming to describe the compound's profile in this group.

Migraine Prophylaxis

Studies have investigated the potential of a combination therapy to be associated with changes in the frequency and severity of migraine attacks. Research in this area used a randomized, controlled study design to compare the combination therapy against a regimen of the standard active comparator alone. Data collection included patient diaries tracking migraine frequency and intensity.


Safety and Tolerability Summary

Research is ongoing to determine whether administration of this compound may be associated with changes in mobility and quality of life scores. The largest Phase 3 trials reported on the overall frequency and nature of adverse events. Trial protocols for this compound typically involved starting participants at a lower dose. The most commonly reported events across studies included headache and nausea.

Findings from Phase 3 trials have contributed to the evidence base concerning this compound.

Key Studies & References Investigating the long-term impact of Histamed administration on mobility and quality of life (Ongoing Study Protocol)

Frequently Asked Questions (FAQ)

Common questions about Histamed (FAQ)


Q: How long does it usually take for Histamed to start working?

Official product information indicates that active components, such as the local anesthetic and counterirritant, are formulated to target localized pain and sensory input quickly. The pharmacological goal of this mechanism is to offer rapid relief at the application site. Regulatory documents do not typically specify a quantitative onset time.

Q: Are the side effects of Histamed permanent or temporary?

According to the official safety documentation, the most common localized effects, such as burning or irritation, are generally transient. However, less frequent skin changes, including skin atrophy (thinning), are specifically noted as being associated with prolonged or inappropriate use of the product.

Q: Is Histamed safe for patients over the age of 65?

Regulatory guidelines advise caution regarding the use of this product in older adults. Official labeling indicates that a reduced frequency or duration of use may be considered for this population to respect safety parameters.

Q: Is Histamed safe for people with kidney problems?

Official guidance advises conditional use for patients who have severe impairment of kidney or liver function. This means that use may be permitted, but only under specific medical monitoring or following dosage adjustments determined by a healthcare professional.

Q: Will Histamed make me feel sleepy or drowsy?

Regulatory documents note that the active antihistamine component may cause effects like drowsiness, dizziness, and sedation. This risk is formally documented, even when the medication is used alone, and may be increased if taken with other central nervous system depressants.

Q: What is the difference between Histamed and a similar drug I used previously?

Official regulatory documentation defines Histamed as a multi-component combination product. Its formulation is designed to provide a comprehensive symptomatic response by simultaneously addressing inflammation, itching, and pain, which distinguishes it from products containing only a single active ingredient.

Q: What does the latest research say about the long-term use of Histamed?

According to official administration protocols, this product is strictly designated for short-term use, often limited to a maximum of 7 consecutive days. This duration is a regulatory safeguard intended to mitigate potential risks associated with prolonged use, such as systemic absorption of the corticosteroid component.

Q: Does Histamed affect my ability to drive or operate machinery?

Official warnings advise that caution is warranted regarding activities like driving or operating heavy machinery. Due to the potential for dizziness and drowsiness from the antihistamine component, it is important to understand how the medication affects the individual before engaging in these activities.

Q: Are there any known severe allergic reactions associated with Histamed?

Regulatory labeling explicitly states that the product is contraindicated for anyone with a known hypersensitivity to any of its components. Severe systemic allergic reactions are formally documented in the official Adverse Reactions section as a possible risk.

Q: What is the main active ingredient in Histamed?

Histamed is a multi-component product that contains eleven distinct active ingredients. While regulatory documents do not label one as the 'main' component, the inclusion of the potent corticosteroid Betamethasone significantly influences the product's official safety restrictions and conditions of use.

Q: Is Histamed considered a 'strong' or potent medicine?

The Glucocorticoid component, Betamethasone, is officially classified in regulatory documents as a potent corticosteroid. This formal classification is a key factor in determining the product's use restrictions and mandated safety warnings.

Q: What do the official guidelines say about using Histamed in adolescents?

Official guidelines outline specific restrictions for children aged 2 to 12 years, limiting use to short durations and small surface areas. For adolescents (typically 12 years and older), official documentation should be referenced for specific guidelines, as usage rules may differ from those for younger children.

Q: What are the common reasons a doctor might decide to discontinue Histamed?

Administration protocols indicate that discontinuation is appropriate once symptoms have resolved. Furthermore, official documentation specifies that treatment should be stopped if there is evidence of systemic adverse effects or localized hypersensitivity reactions.

Q: What should I do if I forget to take a dose of Histamed?

Official patient information provides a specific protocol regarding missed doses. This guidance typically outlines when a missed application should be made up and when it should be skipped to avoid applying two doses too close together.

Q: Is Histamed addictive or habit-forming?

Regulatory documents typically address common public concerns regarding dependency. According to official product information, Histamed is not classified as a controlled substance and is not associated with dependency or habit-forming behavior.

Q: Are there different strengths of Histamed available from the manufacturer?

Official labeling provides a precise list of all available strengths and concentrations of the active ingredients. The product is approved for use in multiple forms, including Cream, Ointment, Solution, or Lotion, each with specific formulations.

Q: Why is Histamed only available by prescription?

Histamed is only available by prescription because it contains the potent corticosteroid Betamethasone. Regulatory agencies mandate medical supervision for use of this class of drug due to the need to monitor for and mitigate the risk of systemic absorption and associated safety concerns, such as HPA axis suppression.

Q: What is the typical shelf life or expiry expectation for Histamed?

Official labeling is required to state the shelf life and expiration date of the product. This date, typically printed on the container, legally guarantees the period during which the medication is certain to maintain its full specifications when stored correctly.

How should Histamed be stored and disposed of?

Official Storage and Disposal Requirements

Histamed must be stored at Controlled Room Temperature, typically ranging from 20 C to 25 C (68 F to 77 F). The regulatory label requires the medication to be protected from excessive heat, moisture, and light, and it must be stored in its original container with the cap tightly closed. The product should not be frozen, as this can compromise the formulation.

For safety, this medication must always be kept out of the sight and reach of children.

Unused or expired Histamed must be disposed of according to official guidance. The preferred method is returning the product to a certified drug take-back location. If this is not possible, the medicine should be mixed with an undesirable substance (such as coffee grounds) and placed in a sealed bag before disposal in the household trash. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Histamed found in:

A-Z Index: